Human Vaccines & Immunotherapeutics

metrics 2024

Pioneering Solutions in Vaccines and Immunotherapy

Introduction

Human Vaccines & Immunotherapeutics, published by TAYLOR & FRANCIS INC, stands at the forefront of immunology and vaccine research, presenting critical advancements and innovative approaches to immunotherapy since its inception in 2012. With an impressive impact factor and rankings in the top quartiles of leading categories such as Immunology, Pharmacology, and Medicine, this journal serves as a vital resource for researchers, healthcare professionals, and students who are dedicated to advancing the understanding and application of vaccines and immunotherapeutic strategies. Offering Open Access options for enhanced visibility and outreach, the journal encourages the dissemination of high-quality research that can drive meaningful impact in public health. Its continuous commitment to excellence is reflected in its ranking metrics—ranking #71 in Pharmacology with a 77th percentile and #69 in Immunology and Allergy with a 70th percentile, ensuring that it remains a preferred forum for notable scholarly contributions in a rapidly evolving field.

Metrics 2024

SCIMAGO Journal Rank0.93
Journal Impact Factor4.10
Journal Impact Factor (5 years)4.20
H-Index93
Journal IF Without Self4.10
Eigen Factor0.02
Normal Eigen Factor4.00
Influence1.01
Immediacy Index0.90
Cited Half Life4.10
Citing Half Life3.80
JCI0.85
Total Documents5677
WOS Total Citations14391
SCIMAGO Total Citations39510
SCIMAGO SELF Citations3251
Scopus Journal Rank0.93
Cites / Document (2 Years)3.81
Cites / Document (3 Years)3.81
Cites / Document (4 Years)3.85

Metrics History

Rank 2024

Scopus

Pharmacology in Pharmacology, Toxicology and Pharmaceutics
Rank #71/313
Percentile 77.32
Quartile Q1
Immunology and Allergy in Medicine
Rank #69/233
Percentile 70.39
Quartile Q2
Immunology in Immunology and Microbiology
Rank #81/236
Percentile 65.68
Quartile Q2

IF (Web Of Science)

BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Rank 45/174
Percentile 74.40
Quartile Q2
IMMUNOLOGY
Rank 74/181
Percentile 59.40
Quartile Q2

JCI (Web Of Science)

BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Rank 53/174
Percentile 69.54
Quartile Q2
IMMUNOLOGY
Rank 57/181
Percentile 68.51
Quartile Q2

Quartile History

Similar Journals

Expert Review of Vaccines

Exploring Breakthroughs in Vaccine Research and Policy.
Publisher: TAYLOR & FRANCIS LTDISSN: 1476-0584Frequency: 12 issues/year

Expert Review of Vaccines, published by Taylor & Francis Ltd, is a pivotal open access journal that has established itself as a leading source of peer-reviewed articles focusing on vaccine research, development, and policy. With an impressive categorization in the top quartile (Q1) across various domains including Drug Discovery, Immunology, Molecular Medicine, and Pharmacology for 2023, this journal plays a crucial role in disseminating high-quality scientific findings that drive advances in the field. Located in the United Kingdom, it serves a global audience of researchers, healthcare professionals, and students seeking to stay abreast of cutting-edge developments in vaccination strategies and technologies. The journal’s Scopus ranks further attest to its excellence, boasting remarkable placements in Pharmacology and Drug Discovery, reflecting its impact and reach. Since transitioning to an open access format in 2023, the journal has enhanced accessibility to vital research, empowering a broader audience to contribute to and engage with the discourse surrounding vaccines. As the field of immunization continues to evolve, Expert Review of Vaccines remains a cornerstone for those committed to advancing knowledge and practice in this essential area of health science.

MICROBIOLOGY AND IMMUNOLOGY

Bridging Decades of Research in Microbiology and Immunology
Publisher: WILEYISSN: 0385-5600Frequency: 12 issues/year

MICROBIOLOGY AND IMMUNOLOGY, an esteemed journal published by WILEY, serves as a vital resource for researchers and professionals in the fields of microbiology, immunology, and virology. With its ISSN 0385-5600 and E-ISSN 1348-0421, this journal has been a cornerstone in scientific literature since its inception in 1977, bridging decades of research and innovation through its comprehensive coverage of emerging trends and discoveries. Although this journal operates without open access, it maintains a commendable presence in academic circles, reflected in its 2023 Quartile rankings of Q3 across the categories of Immunology, Microbiology, and Virology. As part of an important discourse in these disciplines, MICROBIOLOGY AND IMMUNOLOGY ensures its scholarly contributions are relevant to both seasoned researchers and emerging scholars. Positioned in a competitive journal landscape, with Scopus ranks indicating a median percentile across its fields, it remains committed to advancing knowledge through peer-reviewed articles, thereby supporting the continuous evolution of its focus areas. The journal's current scope encompasses topics critical for understanding pathogen-host interactions and the immune response, making it a crucial publication for any academic library or individual scholar dedicated to the biological sciences.

JOURNAL OF INFECTIOUS DISEASES

Pioneering Insights into Infectious Disease Management
Publisher: OXFORD UNIV PRESS INCISSN: 0022-1899Frequency: 24 issues/year

The JOURNAL OF INFECTIOUS DISEASES, published by OXFORD UNIV PRESS INC, is a leading peer-reviewed journal dedicated to advancing the understanding of infectious diseases through high-quality research. With an impressive impact factor reflecting its prominence in the field—ranking in the Q1 category for both Immunology and Allergy and Infectious Diseases—this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike. Its extensive history, spanning over a century since its inception in 1904, highlights its established authority and commitment to the field. Based in the United Kingdom, the journal covers essential topics from clinical management to epidemiological trends, providing vital insights that inform practice and policy. Although the journal is not open access, it remains accessible to a wide audience, ensuring that critical research continues to drive innovation and best practices in infectious disease management.

Vaccines

Transforming immunization strategies with groundbreaking research.
Publisher: MDPIISSN: Frequency: 12 issues/year

Vaccines, published by MDPI in Switzerland, is a leading open access journal that has been at the forefront of vaccine research since its inception in 2013. With an impressive impact factor and consistently ranked in the Q1 and Q2 quartiles across leading categories such as Drug Discovery, Immunology, Infectious Diseases, and Pharmacology, it provides a vital platform for researchers to share their findings and advance the field. The journal is dedicated to delivering high-quality original research articles, reviews, and case studies that address the challenges and innovations in vaccine development and immunization strategies worldwide. Open access since its launch, Vaccines ensures that cutting-edge research is widely available to the global academic community and public health professionals, thereby fostering collaboration and enhancing knowledge in this critical area of public health.

Emerging Microbes & Infections

Pioneering discoveries in microbial health.
Publisher: TAYLOR & FRANCIS LTDISSN: Frequency: 1 issue/year

Emerging Microbes & Infections is a premier open access journal, published by Taylor & Francis Ltd since 2012, dedicated to advancing the understanding of microbial infections and their implications in human health. With an impressive Q1 ranking across multiple categories—including Drug Discovery, Epidemiology, Immunology, and Infectious Diseases—this journal is at the forefront of research in the microbiological sciences. Covering a diverse range of topics, it serves as a vital resource for researchers, healthcare professionals, and students alike. The journal's commitment to open access ensures worldwide dissemination of cutting-edge findings, fostering collaboration and innovation in tackling challenges posed by emerging infections. As part of the thriving academic community in the United Kingdom, Emerging Microbes & Infections plays a crucial role in shaping the future of infectious disease research and public health.

Tuberculosis

Advancing knowledge in the fight against tuberculosis.
Publisher: CHURCHILL LIVINGSTONEISSN: 1472-9792Frequency: 6 issues/year

Tuberculosis is an esteemed peer-reviewed journal specializing in the fields of Infectious Diseases, Immunology, and Microbiology, published by Churchill Livingstone since 1974. With a scope aimed at advancing the understanding and management of tuberculosis and related infectious diseases, the journal provides a platform for innovative research findings, clinical practices, and policy discussions. It is ranked in the Q2 category for both Infectious Diseases and Microbiology (medical), reflecting its significance in the academic community and the impact of its published work. The journal's commitment to openness is evident in its access options, fostering wider dissemination of knowledge. With an impact factor that underscores its relevance, Tuberculosis serves as a crucial resource for researchers, healthcare professionals, and students dedicated to combatting these pressing health challenges. The journal operates from its production headquarters in Edinburgh, Scotland, ensuring a strong connection to the international research community.

ANTIVIRAL RESEARCH

Advancing the Frontiers of Antiviral Science
Publisher: ELSEVIERISSN: 0166-3542Frequency: 12 issues/year

ANTIVIRAL RESEARCH, published by Elsevier, stands at the forefront of the study of antiviral agents and therapy, with a dedicated focus on advancing the understanding of viral infections and their mechanisms. The journal is recognized within the top tier of academic publications, belonging to the prestigious Q1 category in both Pharmacology and Virology as of 2023, ranking 12th out of 313 in Pharmacology and 11th out of 80 in Virology according to Scopus metrics, reflecting its significant impact in the field. With a long-standing history since its inception in 1959, it continues to serve as an essential platform for researchers and health professionals alike, sharing critical findings that drive innovation in antiviral therapeutics. Although it does not currently offer open access options, the journal’s rigorous peer-review process ensures that every published article meets high academic standards, providing invaluable insights for those dedicated to enhancing public health through virology research.

Vaccine

Transforming discoveries into impactful vaccination strategies.
Publisher: ELSEVIER SCI LTDISSN: 0264-410XFrequency: 52 issues/year

Vaccine is a premier academic journal published by Elsevier Science Ltd, dedicated to the field of vaccination and immunization research. With an impact factor and H-index that underscore its significance in the scientific community, this journal has consistently ranked in the Q1 category within various fields, including Immunology and Microbiology, Infectious Diseases, and Public Health. Since its inception in 1983, it has served as a vital resource for researchers, healthcare professionals, and students, providing rigorous peer-reviewed articles that explore important breakthroughs and innovations in vaccine development and deployment. Although it does not operate under an Open Access model, the journal maintains high visibility within academic circles, thanks to its strategic collaborations and widely respected editorial board. By bridging the gaps between laboratory discoveries and clinical applications, Vaccine plays a crucial role in advancing global health initiatives and addressing urgent public health challenges.

American Journal of Clinical and Experimental Immunology

Unlocking the Secrets of Immunity for Clinical Excellence
Publisher: E-CENTURY PUBLISHING CORPISSN: Frequency: 6 issues/year

Welcome to the American Journal of Clinical and Experimental Immunology, a premier publication dedicated to advancing the fields of clinical and experimental immunology. Published by E-CENTURY PUBLISHING CORP, this journal provides a platform for groundbreaking research, case studies, and comprehensive reviews that contribute to our understanding of the immune system and its implications for health and disease. With a focus on disseminating innovative findings and enhancing the dialogue among researchers, practitioners, and students, the journal aims to bridge the gap between laboratory discoveries and clinical applications. Although specific metrics such as the impact factor and Scopus ranks are currently not provided, the journal is committed to maintaining high standards of scholarly publishing and fostering open access to vital research. Located in Madison, WI, and available online via its E-ISSN 2164-7712, this journal is a valuable resource for those wishing to explore the intricacies of immunological research and its applications in clinical practice.

Med

Empowering the Global Medical Community with Knowledge.
Publisher: CELL PRESSISSN: 2666-6340Frequency: 12 issues/year

Med, an esteemed journal published by CELL PRESS, stands at the forefront of interdisciplinary medical research, making significant contributions to the field of Medicine since its inception in 2020. With an impressive Q1 ranking in the Medicine (miscellaneous) category and a notable 96th percentile ranking in General Medicine according to Scopus, this journal is dedicated to disseminating high-quality research that advances medical knowledge and practice. Med provides a platform where researchers, professionals, and students can share their findings and insights, fostering a collaborative environment that bridges various aspects of medicine. While offering a comprehensive body of research, Med is committed to promoting open communication within the scientific community, ensuring that valuable information is accessible to those who seek to enhance their understanding and application of medical science. With a strong presence in the United States and a global readership, Med is poised to influence the future of healthcare significantly.